References
- Drover D, Lemmens H, Naidu S, Cevallos W, Darwish M, Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000; 22: 1443–1461
- Beer B, Ieni JR, Wu WH, Clody D, Amorusi P, Rose J, Mant T, Gaudreault J, Cato A, Stern W. A placebo-controlled evaluation of single, escalating doses of CL 284, 846, a non-benzodiazepine hypnotic. J Clin Pharmacol 1994; 34: 335–334
- Rosen AS, Fournié P, Darwish M, Danjou P, Troy SM. Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 1999; 20: 171–175
- Allen D, Curran HV, Lader M. The effects of single doses of CL 284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. European J Clin Pharmacol 1993; 45: 313–320
- Bhatia SC. Perceptual disturbances with zaleplon. Psychiatr Serv 2001; 52: 109–110
- Liskow B, Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry 2004; 43: 927–8
- Koke SC, Brown EB, Miner CM. Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am J Obstet Gynecol 2002; 29: 551–555
- Pfizer Inc. Geodon® prescribing information. New York, NY May, 2005
- Eli Lilly and Company. Prozac® prescribing information. Indianapolis, IN January, 2005